8/21/2009

GlaxoSmithKline gained accelerated FDA clearance for Hiberix, a vaccine against Haemophilus influenzae Type B, which causes diseases such as meningitis and pneumonia. The approval allows the drug to be used as a booster in children 15 months to 4 years old and is part of an effort to address a shortage of Merck & Co.'s PedvaxHIB.

Related Summaries